Compugen and MedImmune enter exclusive license agreement

MedImmune LLC and Compugen Ltd. penned an agreement for the development of bispecific and multi-specific antibody therapies for cancer. Under terms of the deal, MedImmune paid $10mm for exclusive rights to develop and commercialize multiple antibodies from Compugen’s pipeline. Compugen could receive up to $200mm in regulatory and commercialization milestones for the first project (and additional milestones payable for future candidates), plus tiered sales royalties. The partners did not reveal details of the in-licensed program, but Compugen’s immuno-oncology work includes immune checkpoint inhibitors and other immunomodulators. (The company also has a major immuno-oncology alliance with Bayer; under a 2013 deal, Bayer originally gained rights to two of Compugen’s cancer antibodies, but returned rights to one last year. That deal now solely focuses on the immunotherapy CGEN1500IT.)

Update 12/23/2020

Compugen announced the progress from its ongoing license agreement with AstraZeneca under which the program has achieved a preclinical milestone. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bispecific and multi-specific antibody products based on one of Compugen's pipeline programs, with AstraZeneca responsible for all research, development and commercial activities. In connection with this first milestone, Compugen is entitled to receive a $2M payment from AstraZeneca.

Update 11/16/2022

Compugen expects to receive a milestone payment of $7.5M from AstraZeneca, after AstraZeneca dosed the first patient in its ARTEMIDE Phase II study with AZD2936 for NSCLC.